PCOS Has a New Name. And It's Exposing a Blind Spot We've Had All Along.
This spring, something happened in endocrinology that I've been waiting years for: polycystic ovary syndrome got a new name. As of the May 2026 global consensus published in The Lancet and led by Professor Helena Teede, PCOS is now polyendocrine metabolic ovarian syndrome (PMOS).
It's not just a rebrand. For over 14,000 patients and clinicians surveyed across a decade-long process, the old name was actively harmful, it centered "cysts" that many patients don't even have, and it let everyone, patients and providers alike, treat this as a gynecologic issue with a reproductive fix. PMOS says the quiet part out loud: this is a multisystem, hormonal, metabolic condition that happens to show up in the ovary. The endocrine and metabolic dysfunction is the disease. The ovarian findings are a downstream symptom.
I bring this up because the rename validates something I've been circling clinically for a while: if PMOS is fundamentally a metabolic-endocrine disorder, then every endocrine axis that touches metabolism deserves real scrutiny, not just the reproductive hormones we're trained to chase first. And the axis I think we under investigate the most is the thyroid, specifically Free T3.
The Standard Workup Isn't Wrong. It's Incomplete.
Every major PCOS/PMOS diagnostic framework: Rotterdam, the Endocrine Society, ACOG, AES recommends excluding thyroid dysfunction before confirming a diagnosis. In practice, that almost always means one test: TSH. Maybe a Free T4 if something looks off.
And to be fair, that's not baseless. A comprehensive 2023 narrative review in Frontiers in Endocrinology (Palomba et al.) pulled together the epidemiology, and the associations are real: autoimmune thyroiditis runs roughly threefold to fivefold more common in women with PCOS than without it, and subclinical hypothyroidism shows up at meaningfully higher rates too, depending on the TSH cutoff used. TSH is doing real diagnostic work but it’s only the beginning.
TSH was never designed to tell you whether your tissues are actually getting usable thyroid hormone. It's a pituitary signal, not a peripheral outcome measure. And that distinction matters enormously in a condition defined by metabolic dysfunction.
The Piece Almost No One Is Screening For
Buried in that same review is a finding I think deserves far more attention than it gets: a study by Adamska and colleagues (2019) looked at euthyroid women with PCOS, completely normal TSH, completely normal thyroid panels by conventional standards and put them through a glucose load. What happened to their thyroid hormone conversion afterward was the story. Their peripheral deiodinase activity, the enzymatic process that converts T4 into the metabolically active T3, dropped significantly more than it did in matched women without PCOS. Their Free T3 fell. And that drop tracked directly with insulin, total cholesterol, and triglyceride levels.
In other words: under a metabolic stress test, a subset of PCOS/PMOS patients with a completely "normal" thyroid panel showed impaired conversion of thyroid hormone into its active form and that impairment moved in lockstep with the exact metabolic markers we're already worried about in this population.
That's not a coincidence. T3 is the hormone actually doing the work at the cellular level by regulating basal metabolic rate, and acting directly on gene expression for glucose and lipid handling. If a patient can make normal TSH and normal T4, but her body isn't efficiently converting that T4 into T3 under metabolic load, she can look "thyroid normal" on paper while running a genuine functional deficit exactly where it intersects with insulin resistance, the core lesion of PMOS itself.
Why This Matters Clinically
Here's the pattern I see, and I suspect many of you reading this see it too: a patient with PMOS who is doing the right things with diet, movement, sometimes metformin or inositol and her weight, energy, and lipid panel are still stubbornly resistant to improvement. Her TSH comes back at 2.1. Her Free T4 is mid-range. On paper, thyroid function is "ruled out." But we haven't actually looked at Free T3, and we almost certainly haven't looked at it under any kind of metabolic challenge.
Insulin resistance and thyroid hormone conversion aren't separate problems sitting side by side in these patients, they appear to feed each other. Impaired T4-to-T3 conversion can blunt metabolic rate and worsen lipid handling; worsening insulin resistance may, in turn, further suppress deiodinase activity. That's a self-reinforcing loop, and it's largely invisible if TSH is the only test in the chart.
Where I Land and Where the Evidence Actually Stops
I want to be direct about something, because I think it matters more than the excitement of a new mechanism: the review this piece is built on does not demonstrate that treating Free T3 through T3-containing therapy, T4 dose adjustment, or otherwise improves reproductive or cardiometabolic outcomes in PMOS. The authors are explicit that, across the board, there is currently no RCT-level data establishing that thyroid medications meaningfully improve fertility or cardiometabolic risk in this population. That gap applies to levothyroxine in subclinical hypothyroidism, and it applies just as much to any Free T3 targeted approach.
That said, I'll tell you where my own clinical experience goes beyond what's published. As a certified BHRT provider through WorldLink Medical Academy, I have seen this repeatedly in patients navigating exactly this kind of metabolic complexity, that optimizing Free T3, when the clinical picture supports it, correlates with real improvement: insulin sensitivity moving in the right direction, easier progress on obesity and body composition, and better resilience in the metabolic system overall. I've also observed patterns suggesting a protective relationship between well-optimized thyroid hormone and bone density. These are clinical observations from my own practice, not conclusions this research has proven and I think that distinction matters enough to name explicitly.
What I can say with confidence either way: if you have a PMOS patient who is metabolically stuck despite a "normal" TSH, a full panel TSH, Free T4, Free T3, and thyroid antibodies gives you real information that TSH alone cannot. Whether and how to act on a low-normal or frankly low Free T3 in that context is a case-by-case clinical judgment, built on both the emerging science and what experienced providers are seeing in the room with real patients.
The Bigger Picture
PMOS getting its metabolic identity formally recognized is an invitation to stop treating this as a fertility diagnosis with hormonal side effects, and start treating it as what it actually is: a whole-body endocrine metabolic condition where every hormonal axis that touches insulin sensitivity deserves a real look. The thyroid, and specifically Free T3, is one of the clearest examples of a place we've been under-asking the question.
We don't have the trials yet to tell us exactly what to do about it. But we now have a strong enough signal that we should, at minimum, be looking.
Reference: Palomba S, Colombo C, Busnelli A, Caserta D, Vitale G. Polycystic ovary syndrome and thyroid disorder: a comprehensive narrative review of the literature. Front Endocrinol. 2023;14:1251866.
With warmth,
Alexis C. Ammons, DNP, MSN, FNP-C, APRN Founder & Family Nurse Practitioner, Her NOVA Wellness